rAAV Vector Co-Expression for Multi-Pathology Neurodegeneration Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders such as Parkinson's disease, Multiple System Atrophy, Gaucher's disease, and AADC deficiency are inadequate in restoring dopamine levels, clearing alpha-synuclein aggregates, and preserving dopaminergic transmission, leading to progressive disease progression and significant patient suffering.
Innovation Solution
Development of recombinant adeno-associated viral (rAAV) vectors optimized to express nucleotide sequences encoding AADC, GBA1, and neurotrophic factors like CDNF or GDNF, allowing for synergistic therapeutic effects by simultaneously targeting multiple disease pathologies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neurodegenerative disorders, then disease progression is slow and progressive, but therapeutic effectiveness in restoring dopamine levels and clearing alpha-synuclein aggregates is insufficient
Solution Approach 1:
The patent combines multiple therapeutic genes (AADC, GBA1, and neurotrophic factors) into a single rAAV vector system, enabling simultaneous delivery of multiple therapeutic proteins that work synergistically to restore dopamine levels, clear alpha-synuclein aggregates, and protect neurons, thereby significantly improving therapeutic effectiveness compared to single-treatment approaches
Solution Approach 2:
The invention uses composite gene therapy approaches by co-expressing multiple therapeutic proteins (AADC enzyme for dopamine synthesis, GBA1 for glycocerebroside breakdown, and neurotrophic factors for neuronal protection) within the same viral vector, creating a multi-functional therapeutic composition that addresses multiple pathological mechanisms simultaneously
2Adaptability or versatility
If single-gene therapy approaches are used, then treatment simplicity is maintained, but ability to target multiple disease pathologies simultaneously is limited
Solution Approach 1:
The rAAV vector system is designed with multi-functionality to simultaneously deliver and express multiple therapeutic genes (AADC, GBA1, and neurotrophic factors), enabling a single treatment to address multiple disease pathologies including dopamine depletion, alpha-synuclein aggregation, and neuronal vulnerability, thereby achieving universal therapeutic coverage for neurodegenerative disorders
Solution Approach 2:
Multiple therapeutic gene sequences are merged into a single expression cassette within the rAAV vector, allowing co-expression of AADC, GBA1, and neurotrophic factors from one viral particle, which simplifies administration while maintaining the ability to target multiple pathological mechanisms
3Quantity of substance
If gene expression is not optimized, then vector design is simpler, but therapeutic protein production levels are insufficient
Solution Approach 1:
The patent optimizes nucleotide sequences by modifying codon usage patterns, GC content, and other sequence parameters to enhance transcriptional and translational efficiency, thereby significantly increasing the expression levels of therapeutic proteins (AADC, GBA1, neurotrophic factors) produced from the rAAV vector without altering the amino acid sequences
Data Source
AI summary
Provided is a recombinant adeno-associated viral (rAAV) vector comprising one or two of (a) to (c): (a) a nucleotide sequence encoding aromatic L-amino acid decarboxylase (AADC), (b) a nucleotide sequence encoding glucocerebrosidase (GBA1); and (c) a nucleotide sequence encoding a neurotrophic factor (NTF), such as cerebral dopamine neurotrophic factor (CDNF) or glial cell derived neurotrophic factor (GDNF), for treating neurodegenerative disorders, particularly Parkinson's disease (PD), Multiple system atrophy (MSA), Gaucher's disease (GD), and other proteinopathies. Also provided herein are viral particles comprising the rAAV vector, a pharmaceutical composition comprising the viral particles, and uses thereof.